Skip to main
ARMP
ARMP logo

ARMP Stock Forecast & Price Target

ARMP Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Armata Pharmaceuticals Inc. is advancing its proprietary bacteriophage-based technology, focusing on treating antibiotic-resistant bacterial infections, which aligns with the increasing demand for innovative therapies within the medical community. The company has made significant progress by completing enrollment in key clinical trials, such as the Phase 2 Tailwind study and the Phase 1b/2a diSARM study, which are critical for generating pivotal data that could enhance the commercial viability of its therapies. Preliminary data suggests that the lead candidate, AP-PA02, demonstrates effective outcomes and a favorable safety profile, indicating potential market disruption and the ability to meet the urgent needs of healthcare professionals and patients alike.

Bears say

The financial outlook for Armata Pharmaceuticals is negatively impacted by the substantial risks associated with the potential failure of clinical trials, which could hinder the company's ability to deliver effective therapies. Moreover, the company faces challenges in securing adequate funding, essential for progressing its drug candidates through the development stages, which raises concerns about its financial stability and operational continuity. Additionally, issues related to sample sizes and patient data in trials have raised doubts regarding the statistical significance of results, further complicating Armata's path to successful product development and market entry.

ARMP has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Armata Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Armata Pharmaceuticals Inc (ARMP) Forecast

Analysts have given ARMP a Strong Buy based on their latest research and market trends.

According to 3 analysts, ARMP has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Armata Pharmaceuticals Inc (ARMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.